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The ease with which whole genome sequence (WGS) information can be obtained is rapidly approaching
the point where it can become useful for routine clinical care. However, signiﬁcant barriers will inhibit
widespread adoption unless clinicians are able to effectively integrate this information into patient care
and decision-making. Electronic health records (EHR) and clinical decision support (CDS) systems may
play a critical role in this integration. A previously published technical desiderata focused primarily on
the integration of genomic data into the EHR. This manuscript extends the previous desiderata by specif-
ically addressing needs related to the integration of genomic information with CDS. The objective of this
study is to develop and validate a guiding set of technical desiderata for supporting the clinical use of
WGS through CDS. A panel of domain experts in genomics and CDS developed a proposed set of seven
additional requirements. These desiderata were reviewed by 63 experts in genomics and CDS through
an online survey and reﬁned based on the experts’ comments. These additional desiderata provide impor-
tant guiding principles for the technical development of CDS capabilities for the clinical use of WGS
information.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Rapid genomic sequencing, including whole genome sequenc-
ing (WGS) and exome sequencing, is the future paradigm of clinical
genetic testing [1]. With a patient’s entire genome readily available
to a clinician at the point of care, WGS may offer many beneﬁts to
traditional single gene testing. Currently, the effective use of single
gene testing is inhibited by several factors including the need for
clinical indication prior to ordering, the time delay between test
ordering and the return of results, and ﬁnancial constraints for sin-
gle gene tests [2]. WGS will likely overcome many such barriers in
the future. For instance, with WGS information readily available,
pathogenic variants in disease-causing genes can be made known
to the clinician much earlier in the decision-making process to
aid in differential diagnosis [3]. Likewise, important but clinically
under-utilized use cases such as pharmacogenomics may nowbecome more clinically and ﬁnancially feasible than under the
current genetic testing paradigm [4]. Indeed, the cost and value
of WGS is now at a point at which health care providers are
sequencing a patient’s genome for unique clinical scenarios [5,6].
As a result, it may be soon when WGS becomes a larger part of
routine clinical care [1].1.1. Challenge of genome data in the clinical setting
While WGS offers many opportunities to enhance clinical care,
were it to be made widely available for routine clinical care today,
the effective use of WGS information would be hindered by
signiﬁcant barriers. These barriers include inadequate laboratory
reporting methods, the complexity of genetic analysis, lack of phy-
sician proﬁciency in genetic analysis, and the insufﬁcient number
of genetics professionals in the workforce [7,8]. As clinicians are
already burdened with signiﬁcant time constraints, adding an
additional layer of WGS information that they are required to
review, integrate with other clinical parameters, and translate into
appropriate clinical actions is unlikely to be successful without
assistance [9]. This challenge is ampliﬁed by the rapidly evolving
Table 1
Potential examples of CDS leveraging WGS data.
CDS type Clinical genomics example
Medication dosing
support
CDS automatically adjusts warfarin dosing as a result of known alleles in the VKORC1 and CYP2C9 genes
Order facilitators An order for colonoscopy is recommended at a younger age as a result of known pathogenic mutations in genes associated with colon
cancer
Alerts and reminders During medication ordering, gene variants known to affect drug pharmacokinetics are checked and clinicians are alerted to potential gene-
drug interactions
Relevant information
display
Context aware infobuttons in the problem list leverage genome data to provide genetic risk information for a patient with breast cancer
Expert systems The EHR provides a 10-year cardiovascular disease risk score based on clinical, environmental, and genetic risk factors
Workﬂow support The EHR schedules a genetic counseling consultation during prenatal visit due to presence of an X-linked disease gene variant
Table 2
Desiderata for the integration of genomic data into EHRs described by Masys et. al.
1 Maintain separation of primary molecular observations from the clinical interpretations of those data
2 Support lossless data compression from primary molecular observations to clinically manageable subsets
3 Maintain linkage of molecular observations to the laboratory methods used to generate them
4 Support compact representation of clinically actionable subsets for optimal performance
5 Simultaneously support human-viewable formats and machine-readable formats in order to facilitate implementation of decision support rules
6 Anticipate fundamental changes in the understanding of human molecular variation
7 Support both individual clinical care and discovery science
Table 3
Additional desiderata for the technical integration of WGS with CDS.
8 CDS knowledge must have the potential to incorporate multiple genes and clinical information
9 Keep CDS knowledge separate from variant classiﬁcation
10 CDS knowledge must have the capacity to support multiple EHR platforms with various data representations with minimal modiﬁcation
11 Support a large number of gene variants while simplifying the CDS knowledge to the extent possible
12 Leverage current and developing CDS and genomics standards
13 Support a CDS knowledge base deployed at and developed by multiple independent organizations
14 Access and transmit only the genomic information necessary for CDS
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tions [10].
1.2. Potential of clinical decision support
Clinical decision support (CDS) integrated into the clinician’s
workﬂow provides a practical solution to allow clinicians to pro-
vide effective clinical care using genomic information [11,12].
CDS entails providing clinicians, patients, and other healthcare
stakeholders with pertinent knowledge and person-speciﬁc infor-
mation, intelligently ﬁltered or presented at appropriate times, to
enhance health and healthcare [13]. Examples of point-of-care
CDS include medication dosing support, order facilitators, alerts
and reminders, relevant information display, expert systems, and
workﬂow support [14]. CDS knowledge, which supports these
types of CDS, is used to process clinical data to provide patient-
speciﬁc advice, recommendations, or information. Table 1 provides
summary of CDS types and potential examples of WGS-enabled
CDS.
When developed and implemented properly, CDS has the ability
to process large amounts of complex data, such as WGS data, and
present actionable, evidence-based recommendations to clinicians
at the point of care [15]. In doing so, CDS has been shown to be
effective in reducing errors, improving clinician performance, and
ultimately improving the quality of care in clinical settings [16].
Furthermore, CDS is able to translate research discoveries into clin-
ical care much more efﬁciently than other traditional methods of
knowledge translation [17]. Indeed, CDS may be essential to meet-
ing the demands of WGS at the point of care [18].1.3. Masys et al. desiderata for integration of genomic information
with EHRs
To provide guidance on how to integrate genomic information
within the EHR, Masys et al. [19] developed a set of guiding prin-
ciples for the technical integration of genomic information into
the EHR. Their summarized desiderata is outlined in Table 2. While
this paper provides a strong foundation for integration of genomic
information within the EHR, in our experience developing CDS
capabilities for WGS, we found that it did not fully address all
the needs of WGS integration with CDS.
To address this need, we assembled a core group of domain
experts in genomics and CDS to deﬁne additional desirable
functional characteristics for CDS capable of incorporating WGS
at the point of care within an EHR. These additional requirements
were then validated and assessed for importance among a larger
group of domain experts in genomics and CDS. These additional
desiderata, described in Table 3, are intended to augment the
original Masys et al. desiderata and provide further guidance to
system developers on important requirements to consider when
developing health IT systems and CDS for WGS information. Of
note, the requirements described in this desiderata represent
current and potential needs according to our current understand-
ing. Nevertheless, future research and development may require
additional requirements to be added or compel current require-
ments to be removed from the desiderata. As such, this initial set
of requirements should be viewed as an evolving set of require-
ments that informs and is informed by ongoing research and devel-
opment in this ﬁeld.
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A core group of domain experts in genomics and CDS was
assembled to review needs for WGS CDS. This group of domain
experts derived a set of additional desiderata by consensus. The
members of the core group consisted of the authors of this manu-
script and described in Appendix A. We sought to improve, reﬁne,
and validate our initial set of requirements by seeking additional
input and qualitative feedback from a wider community of domain
experts in genomics and CDS. To obtain this feedback, an
anonymous, IRB-approved survey was distributed electronically
to e-mail discussion lists of relevant expert groups [20]. Partici-
pants included members of the HL7 Clinical Genomics Workgroup,
HL7 CDS Workgroup, AMIA Genomics Workgroup, AMIA CDS
Workgroup, Open Source Electronic Health Record Agent (OSEHRA)
Genomics Workgroup, the developers of ClinVar, University of
Utah Program in Personalized Health Care, and our own profes-
sional contacts. The survey instrument was available from 8/13/
2013 through 8/30/2013. Each requirement was listed and summa-
rized on a separate page with a 5-point Likert scale assessing the
participant’s opinion regarding the importance of each require-
ment (very important, important, neither important nor unimpor-
tant, unimportant, very unimportant, and unsure/no opinion/
blank). The full survey is available in Appendix B. Survey responses
were analyzed and visualized using spreadsheet software. Qualita-
tive feedback was reviewed by the core panel, and feedback was
incorporated into the desiderata where appropriate. Participant
feedback, resulting modiﬁcations, and core group responses are
available in Appendix C.3. Additional desiderata for the technical integration of WGS
with CDS
The ﬁnal desiderata is summarized in Table 3, listed in order of
importance as assessed by the community of experts. All proposed
requirements were judged to be important (with high signiﬁcance)
by the community of experts. The explanation and reasoning for
each additional requirement is provided here.
3.1. CDS knowledge must have the potential to incorporate multiple
genes and clinical information. (Requirement #8)
A relatively small number of Mendelian diseases, such as cystic
ﬁbrosis and sickle-cell anemia, are affected by variants within a
single gene responsible for producing the characteristic phenotype.
As a result, such cases are fairly straightforward to assess. With
nearly every human condition affected one way or another by a
genetic inﬂuence, most diseases, in particular common diseases,
are caused or affected by multiple genetic inﬂuences and environ-
mental factors. For example, there are potentially hundreds of
genetic loci contributing to type 2 diabetes risk [21]. In order to
provide an accurate risk assessment and decision support, all rele-
vant genetic loci, relevant clinical factors (e.g. age, weight, health
history, co-morbidities), and environmental inﬂuences (e.g. diet,
physical activity, stress) need to be considered. Furthermore, it
may not always be the case that all necessary data is in one central
location. Therefore, CDS for the WGS must have the capacity to
leverage and incorporate several pieces of information from multi-
ple genomic and non-genomic data sources.
3.2. Keep CDS knowledge separate from the variant classiﬁcation.
(Requirement #9)
Masys et al. describe the importance of separating molecular
observations (e.g. DNA sequence) from variant classiﬁcation (e.g.pathogenicity classiﬁcations) due to the need to update variant
interpretation as genome knowledge changes and grows over time.
To illustrate, one study found that over a seven year period, 14.5%
of reported variant classiﬁcations had to be reclassiﬁed [22]. Like-
wise, it is also essential to separate CDS knowledge from both
molecular observations and variant classiﬁcation. CDS must have
the ability to manage evolving and frequently changing gene
variant interpretations efﬁciently without requiring changes to
the underlying CDS knowledge each time a variant’s classiﬁcation
changes. Separation of CDS knowledge from variant interpretation
allows CDS knowledge to be more efﬁciently handled and
maintained.
3.3. Have the capacity to support multiple EHR platforms with various
data representations with minimal modiﬁcation. (Requirement #10)
The reality of the health information environment in the US
today is that multiple healthcare organizations use multiple EHR
and health information management systems [23]. Often, these
health information management solutions store and represent
the same health information differently. This can be a challenge
when trying to harness the information within different health IT
systems in different organizations to provide CDS. Due to the need
to distribute and share WGS enabled CDS knowledge across
multiple organizations (see next requirement), the CDS architec-
ture would ideally be EHR agnostic, where CDS knowledge can
be developed once, and then run consistently anywhere. A number
of initiatives aimed at supporting this type of architecture are
underway, including the Health eDecisions initiative, OpenCDS,
the SMART platform, and the CDS Consortium, to name a few.
3.4. Support a large number of gene variants while simplifying the CDS
knowledge to the extent possible. (Requirement #11)
There are roughly 1200 known variants in the adenomatous
polyposis coli (APC) gene, a gene associated with a rare form of
colon cancer [24]. Likewise, there are nearly 2000 known variants
in the cystic ﬁbrosis gene CFTR [25]. Given the potentially high
number of variants per gene, it may be inefﬁcient to create CDS
knowledge for every known variant in each disease-causing gene.
Furthermore, as novel variants are discovered, it will be difﬁcult
to update CDS knowledge for every gene variant that is discovered.
Therefore, to manage this complexity, variants with the same or
similar clinical impact should be classiﬁed accordingly. CDS knowl-
edge can then be simpliﬁed by developing logic or rules which
leverages the variant interpretation rather than the speciﬁc vari-
ant. Nevertheless, in cases where a particular variant has a unique
and clinically important impact or where machine learning CDS
models could utilize individual variants or combinations of vari-
ants within a single gene, genetic information at the variant level
should still be accessible to CDS knowledge. In summary, CDS
knowledge can be greatly simpliﬁed by classifying variants into
groups of common clinical impact, while still supporting inferenc-
ing at the individual variant level where necessary.
3.5. Leverage current and developing CDS and genomics standards.
(Requirement #12)
Both the CDS and genomics ﬁelds have beneﬁted from extensive
research and development over the years. Indeed, both ﬁelds have
well developed infrastructure and standards to support its uses.
Therefore, it is important to leverage these standards and infra-
structure. Examples include using HGVS and dbSNP to represent
speciﬁc molecular observations; ACMG recommendations for
variant classiﬁcation; HL7 Clinical Genomics standards for the
representation of genetic information; Arden Syntax, GELLO, GLIF3,
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CDS knowledge representation; the HL7 Decision Support Service
standard and HL7 Infobutton standard for delivering CDS as a
service; and open-source, standards-based resources such as
OpenCDS. While many of these standards and resources may not
be completely sufﬁcient for meeting the needs of CDS for WGS, it
still represents signiﬁcant relevant effort. It will be important to
leverage current and developing CDS and genomics infrastructure,
standards, and knowledge.
3.6. Support a CDS knowledge base deployed at and developed by
multiple independent organizations. (Requirement #13)
With the potential for genomic information to impact nearly
every clinical decision and the clinical application of genomics rap-
idly evolving, the time and cost for a single entity or organization
to manually create and update CDS knowledge will be challenging.
Indeed, it is unlikely that a single health care organization will be
able to author and manage all CDS knowledge for all WGS use
cases. Furthermore, there should be an efﬁcient and scalable mech-
anism to consistently modify CDS knowledge everywhere it is
deployed. Ideally, a standardized CDS infrastructure would allow
multiple health care organizations, public or private entities, or
individuals to create, publish, and distribute CDS knowledge efﬁ-
ciently to multiple consuming health care organizations. Such an
approach will allow a specialized entity (e.g. pharmacogenomics
experts) to develop and manage CDS knowledge and subsequently
distribute to ‘subscribing’ health care organizations. With an eco-
system of CDS knowledge developed independently by multiple
content developers, it becomes more feasible for health care orga-
nizations to have affordable access to comprehensive, up-to-date,
and accurate CDS knowledge for the entire genome.
3.7. Access and transmit only the genomic information necessary for
CDS. (Requirement #14)
The separation of CDS knowledge from molecular observations
and variant interpretations will require relevant genetic informa-
tion being accessed and sent to a CDS engine (or equivalent) for
processing. It will be inefﬁcient and insecure to transmit an entire
genome ﬁle for every CDS knowledge. The processing capacity
required to transmit and sift through an entire genome for CDS
knowledge will hinder the ability to provide CDS at the point of
care in real-time. Furthermore, HIPAA requires that only the min-
imum protected health information needed to satisfy a particular
purpose or carry out a function be used or transmitted [26]. There-
fore, a CDS architecture must only transmit the relevant genes and
any associated molecular observations, variant interpretations, and
associated clinical information.4. Discussion
To guide development of CDS capabilities for WGS information,
we identiﬁed several additional requirements that were not
addressed in a previously published work on integrating genomic
information with EHRs [19]. These additional proposed require-
ments were reviewed by a community of experts and found to
be important. While the Masys et al. desiderata primarily focused
on the integration of genomic information within the EHR, our
desiderata focus largely on the integration of genomic information
with CDS capabilities. The combination of both desiderata is
important to leverage WGS within EHRs using CDS. Given the
important need to provide CDS capable of supporting WGS infor-
mation at the point of care, and the requirements to support boththe Masys et al. and these desiderata, a novel CDS architecture
capable of supporting these requirements will need to be designed,
developed, and evaluated. Due to the scope and complexity of
integrating WGS information with CDS as outlined in the desider-
ata, we propose a CDS architecture that utilizes principles of a
service-oriented architecture (SOA). SOA is a software design
methodology based on a collection of separate, independent soft-
ware components known as services, which are self-contained
and have well-deﬁned capabilities [27]. Accordingly, we are cur-
rently developing a prototype CDS architecture that is based on
the principles of SOA and is capable of supporting WGS informa-
tion in a manner consistent with the desiderata described in this
manuscript and the Masys’ paper. Once such a prototype is devel-
oped and tested, clinical scenarios will test the feasibility of this
approach. Finally, once testing is complete, implementing as a pilot
study will be important to validate the solution in a real clinical
setting. As a result of these efforts, it is likely that additional
requirements may be identiﬁed for inclusion in the desiderata.
As such, this proposed set of desiderata should not be considered
a ﬁnal authoritative set, but rather a foundation upon which fur-
ther requirements may be added in the future.
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